Rockwell Medical (NASDAQ:RMTI - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $23.65 million for the quarter. Investors interested in listening to the company's conference call can do so using this link.
Rockwell Medical Stock Up 7.9 %
RMTI opened at $1.64 on Thursday. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 1-year low of $1.35 and a 1-year high of $5.15. The company has a market capitalization of $53.00 million, a PE ratio of -32.80 and a beta of 1.56. The firm's 50 day simple moving average is $1.93 and its two-hundred day simple moving average is $2.67.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on RMTI. RODMAN&RENSHAW raised shares of Rockwell Medical to a "strong-buy" rating in a research note on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Rockwell Medical in a research note on Thursday, November 14th. They issued a "buy" rating and a $5.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Rockwell Medical in a research note on Monday, December 23rd. Finally, StockNews.com cut shares of Rockwell Medical from a "buy" rating to a "hold" rating in a research note on Friday, December 20th.
Check Out Our Latest Stock Report on Rockwell Medical
Rockwell Medical Company Profile
(
Get Free Report)
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rockwell Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rockwell Medical wasn't on the list.
While Rockwell Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
